←
GoggleDocs2,689 posts
GoggleDocs avatar

GoggleDocs

@GoggleDocs

🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube youtube.com/c/GoggleDocs |Educate, Motivate, Activate!

◷ Joined October 2020▧ 782 Photos and videos
Professor Kamlesh Khunti avatar
⟳ GoggleDocs retweeted
Professor Kamlesh Khunti@kamleshkhunti·Oct 30

CGM may have an important role in type 2 diabetes even for people who are not using insulin. @NEJM In this 26-week primary care RCT of 283 adults: 📉 HbA1c: 7.2% with CGM vs 8.0% with routine care ⏱️ Time in range: +21 percentage points ✅ No severe hypoglycaemia reported For patients: seeing glucose responses in real time may help connect food, activity and treatment with glucose levels. Need robust data on cost-effectiveness and in which patient population with T2 diabetes @AskDrShashank

Post attachment
Dr Amar Puttanna 🎸 avatar
⟳ GoggleDocs retweeted
Dr Amar Puttanna 🎸@AmarPut·Oct 15

@NICEComms expects benefit in a frail, vulnerable cohort…. Show me the evidence… potential for harm has not been mitigated and needs to be balanced/addressed…

Professor Kamlesh Khunti avatar
⟳ GoggleDocs retweeted
Professor Kamlesh Khunti@kamleshkhunti·Oct 14

🧓 Can GLP-1 RAs help preserve function in people with diabetes? In 73,592 propensity-matched pairs, GLP-1 RA initiation vs DPP-4 inhibitors was associated with: 📉 Less frailty progression 🚶 13% lower fall rate (IRR 0.87, 95% CI 0.84–0.91) ⚠️ Associations were weaker in severe baseline frailty. Real-world evidence, not proof of causality. #Diabetes #Frailty #GLP1RA #Geriatrics dom-pubs.onlinelibrary.wiley… @AskDrShashank

Post attachment
Professor Kamlesh Khunti avatar
⟳ GoggleDocs retweeted
Professor Kamlesh Khunti@kamleshkhunti·Oct 14

🩺 HbA1c vs fasting glucose: Which better predicts cardiometabolic multiple long term conditions (multimorbidity) in people without diabetes? Our study led by @scelee1 & Setor In 2,233 adults in England followed for 12–15 years, both markers were associated with future cardiometabolic multimorbidity—but HbA1c was the stronger predictor. 📈 Each 1% higher HbA1c: ~2× higher odds 🔬 HbA1c improved risk discrimination more than fasting glucose. HbA1c help identify long-term cardiometabolic risk earlier? #Diabetes #CardiometabolicHealth #Prevention #PublicHealth sciencedirect.com/science/ar… @AskDrShashank @LDC_tweets @uniofleicester

Post attachmentPost attachment
Neil Floch MD avatar
⟳ GoggleDocs retweeted
Neil Floch MD@NeilFlochMD·Oct 7

GLP-1 are a life changing and possibly a humanity changing group of medications. The fact that insurance will not cover them should cause patients to be extremely angry. Obesity is the mother of chronic disease. Successful obesity treatment should not be discriminated against.

It seems that GLP-1s reduce the whole-body risk of disease. Across 5 RCTs, semaglutide lowered blood-based risk scores for diabetes, and in 4 of 5 for AFIB, heart failure and coronary disease. Just fascinating!

Post attachment
Brendon Neuen avatar
⟳ GoggleDocs retweeted
Brendon Neuen@brendonneuen·Oct 8

Colleagues, we need your help - We're seeking nephrologists' perspectives on management of iron deficiency in CKD. The survey takes <5 minutes & will help shape the design of a new international randomised trial rnsapmredcap.nslhd.health.ns… Thanks for sharing with your networks

Post attachmentPost attachment
Dr. Shashank Joshi avatar
⟳ GoggleDocs retweeted
Dr. Shashank Joshi@AskDrShashank·Oct 6

Next-Generation Obesity and Diabetes Therapy CagriSema — REIMAGINE 2 HbA1c reduction: 1.9% Weight reduction: 14.6% TIR increased from 52.3% to 88.0% at week 68 Retatrutide — TRIUMPH-2 Major weight reduction with accompanying improvement in glycaemic control. Survodutide — SYNCHRONIZE-2 -Significant weight loss and HbA1c reduction, -gastrointestinal adverse effects ( concerning point) Amylin-Based Therapies -An emerging major pathway for obesity treatment, -cagrilintide and eloralintide. Oral Incretin Therapies -oral semaglutide -orforglipron. Once-Weekly Basal Insulin

Post attachment
GoggleDocs avatar
GoggleDocs@GoggleDocs·Sep 29

🚨Retatrutide TRIUMPH-1 (NEJM) 80 wk weight: ⤵️25% on 12 mg vs -3.9% placebo. ⤵️28.3% headline = efficacy estimand. 👉9 vs 12 mg near identical; only 54% still on 12 mg at wk 80 ⚠️⚡️Dysaesthesia, hypotension, MACE 9 v 1 (small n) Treat to target, not max dose❓ 🔗 nejm.org/doi/full/10.1056/NE…

Post attachment
1990sUtd avatar
⟳ GoggleDocs retweeted
1990sUtd@1990sUtd·Sep 28

Marvellous edit 😅

0:28
Don McGowan avatar
⟳ GoggleDocs retweeted
Don McGowan@donmcgowan·Sep 16

Dear @Ofcom Please can you clarify to the nation why this is allowed under your current broadcasting rules? A sitting MP [sometimes] on a TV channel he part owns, delivering a party political broadcast on behalf of Reform UK? Seriously ... WTF?

Nigel Farage exposes how Labour and the Tories hand out government contracts to their donors. Under Reform UK, contracts will benefit the taxpayer - not our donors.

0:22
Dr Amar Puttanna 🎸 avatar
⟳ GoggleDocs retweeted
Dr Amar Puttanna 🎸@AmarPut·Sep 4

Excited to work with @ATTDconf 👉🏽Management of older adults, technology & diabetes👈🏽 ❓How do we manage older adults with diabetes ❓How do we balance intervention with support and QOL ❓What is the role of technology & how can we simplify/facilitate us02web.zoom.us/webinar/regi…

Post attachment
Brendon Neuen avatar
⟳ GoggleDocs retweeted
Brendon Neuen@brendonneuen·Sep 2

“CKD is not really a disease… trials don’t necessarily translate to living longer” Not really sure where to start here. But trials in the last 20 years in which CKD therapies extend survival: #DAPACKD HR 0.69 (0.53-0.88) #FIDELITY HR 0.89 (0.79-1.00) #FLOW HR 0.80 (0.67-0.95)

lol. only talking about HF. TOPCAT in my view was positive trial due to fishiness in certain regions. SPIRITHF is harder to reconcile since stopped early. CKD is not really a disease and the outcomes from the trials don't necessarily translate to living better or longer. if you care so much about evidence why not advocate for a head to head trial? why are makers of finenrone and the academics who promote it afraid of elevating the best evidence?

GoggleDocs avatar
GoggleDocs@GoggleDocs·Aug 29

#ESCcongress2025 💊 STAREE in NEJM: atorvastatin 40mg vs placebo, 9,971 adults aged 70+, 5.9 yrs 📉 Major CV events HR 0.70 ✅ NNT 37 ⚖️ Disability-free survival HR 0.94 (0.84–1.05) ❌ 📊 CV death HR 1.00 Fewer heart attacks. Not a longer or more independent life

Post attachment